Research graph
References from Pharmacological inhibition of the SUMOylation pathway: Mechanisms, inhibitors and therapeutic opportunities. Local targets link to admitted publications; unresolved targets remain external evidence.
A review of visualisations of protein fold networks and their relationship with sequence and function
10.1111/brv.12905 · 2023 · External reference
dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications
10.1093/nar/gkab1017 · 2022 · External reference
Posttranslational modifications in proteins: resources, tools and prediction methods
2021 · External reference
Protein post-translational modifications in auxin signaling
10.1016/j.jgg.2023.07.002 · 2024 · External reference
Protein post-translational modification by lysine succinylation: Biochemistry, biological implications, and therapeutic opportunities
10.1016/j.gendis.2022.03.009 · 2023 · External reference
Deciphering the potential role of post-translational modifications of histones in gastrointestinal cancers: a proteomics-based review with therapeutic challenges and opportunities
10.3389/fonc.2024.1481426 · 2024 · External reference
Global Analysis of SUMO-Binding Proteins Identifies SUMOylation as a Key Regulator of the INO80 Chromatin Remodeling Complex
10.1074/mcp.m116.063719 · 2017 · External reference
Exploring potential targets for natural product therapy of DN: the role of SUMOylation
2024 · External reference
Paradoxes of Cellular SUMOylation Regulation: A Role of Biomolecular Condensates?
10.1124/pharmrev.122.000784 · 2023 · External reference
Paralogue-Specific Roles of SUMO1 and SUMO2/3 in Protein Quality Control and Associated Diseases
10.3390/cells13010008 · 2023 · External reference
Identification of SUMO Targets Associated With the Pluripotent State in Human Stem Cells
10.1016/j.mcpro.2021.100164 · 2021 · External reference
Synthetic inhibition of the SUMO pathway by targeting the SAE1 component via TAK-981 compound impairs growth and chemosensitizes embryonal and alveolar rhabdomyosarcoma cell lines
10.1007/s11010-025-05336-6 · 2025 · External reference
SUMOylation and DeSUMOylation: Prospective therapeutic targets in cancer
10.1016/j.lfs.2023.122085 · 2023 · External reference
Signalling mechanisms and cellular functions of SUMO
10.1038/s41580-022-00500-y · 2022 · External reference
SUMO and cellular adaptive mechanisms
10.1038/s12276-020-0457-2 · 2020 · External reference
Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
10.1186/s12929-024-01060-3 · 2024 · External reference
SUMOylation indirectly suppresses activity of the HIF-1α pathway in intestinal epithelial cells
10.1016/j.jbc.2023.105280 · 2023 · External reference
Reduced SUMOylation of Nrf2 signaling contributes to its inhibition induced by amyloid-β
10.1016/j.neulet.2023.137118 · 2023 · External reference
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model
10.1136/gutjnl-2021-324834 · 2022 · External reference
Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer
10.1021/acs.jmedchem.0c01491 · 2021 · External reference
SUMO: From Bench to Bedside
10.1152/physrev.00025.2019 · 2020 · External reference
SUMO conjugation - a mechanistic view
10.1515/bmc-2016-0030 · 2017 · External reference
Current Status of SUMOylation Inhibitors
10.2174/0929867327666200810135039 · 2021 · External reference
Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor
10.1038/nchembio.2463 · 2017 · External reference
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
10.1158/2767-9764.crc-25-0243 · 2025 · External reference
Synthesis of 2′,3′,4′-trihydroxyflavone (2-D08), an inhibitor of protein sumoylation
10.1016/j.bmcl.2014.01.010 · 2014 · External reference
Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2
10.1021/cb400630z · 2013 · External reference
Identification and characterization of a new chemotype of noncovalent SENP inhibitors
10.1021/cb400177q · 2013 · External reference
SUMO Interacting Motifs: Structure and Function
10.3390/cells10112825 · 2021 · External reference
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
10.1136/gutjnl-2018-317856 · 2020 · External reference
AZD1390, an ataxia telangiectasia mutated inhibitor, attenuates microglia-mediated neuroinflammation and ischemic brain injury
10.1111/cns.14696 · 2024 · External reference
RanBP2/Nup358 mediates sumoylation of STAT1 and antagonizes interferon-α-mediated antiviral innate immunity
10.3390/ijms25010299 · 2024 · External reference
N-MYC-interacting protein enhances type II interferon signaling by inhibiting STAT1 sumoylation
10.1096/fj.202301450rr · 2023 · External reference
SENP3 affects the expression of PYCR1 to promote bladder cancer proliferation and EMT transformation by deSUMOylation of STAT3
10.18632/aging.204333 · 2022 · External reference
Regulation of transforming growth factor-β signalling by SUMOylation and its role in fibrosis
10.1098/rsob.210043 · 2021 · External reference
SUMOylation Fine-Tunes Endothelial HEY1 in the Regulation of Angiogenesis
10.1161/circresaha.123.323398 · 2024 · External reference
SUMOylation modulates the stability and function of PI3K-p110β
10.1007/s00018-021-03826-6 · 2021 · External reference
PDPK1 regulates autophagosome biogenesis by binding to PIK3C3
10.1080/15548627.2020.1817279 · 2021 · External reference
SUMO modifies GβL and mediates mTOR signaling
10.1016/j.jbc.2024.105778 · 2024 · External reference
Sumoylation increases HIF-1alpha stability and its transcriptional activity
10.1016/j.bbrc.2004.09.068 · 2004 · External reference
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia
10.1016/j.cell.2007.08.045 · 2007 · External reference
PIASy stimulates HIF1α SUMOylation and negatively regulates HIF1α activity in response to hypoxia
10.1038/onc.2010.297 · 2010 · External reference
RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation
10.1038/ncb1716 · 2008 · External reference
SUMOylation Wrestles With the Occurrence and Development of Breast Cancer
2021 · External reference
MYC dysfunction modulates stemness and tumorigenesis in breast cancer
10.7150/ijbs.51458 · 2021 · External reference
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
10.1016/j.cmet.2017.09.009 · 2017 · External reference
Central role of SUMOylation in the regulation of chromatin interactions and transcriptional outputs of the androgen receptor in prostate cancer cells
10.1093/nar/gkae653 · 2024 · External reference
N-MYC regulates cell survival via eIF4G1 in inv(16) acute myeloid leukemia
10.1126/sciadv.adh8493 · 2024 · External reference
Acute Myeloid Leukemia-Related Proteins Modified by Ubiquitin and Ubiquitin-like Proteins
10.3390/ijms23010514 · 2022 · External reference
METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma
10.1038/s44318-024-00299-8 · 2024 · External reference
Disruption of the KLHL37-N-Myc complex restores N-Myc degradation and arrests neuroblastoma growth in mouse models
10.1172/jci176655 · 2025 · External reference
SENP1-mediated deSUMOylation of YBX1 promotes colorectal cancer development through the SENP1-YBX1-AKT signaling axis
10.1038/s41388-025-03302-6 · 2025 · External reference
SUMOylation-regulated genes in colon cancer: expression patterns and clinical implications
10.1007/s12672-025-02614-z · 2025 · External reference
The Role of Protein SUMOylation in Human Hepatocellular Carcinoma: A Potential Target of New Drug Discovery and Development
10.3390/cancers13225700 · 2021 · External reference
Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation
10.1016/j.labinv.2022.100011 · 2023 · External reference
Aim2 Couples With Ube2i for Sumoylation-Mediated Repression of Interferon Signatures in Systemic Lupus Erythematosus
10.1002/art.41677 · 2021 · External reference
SENP7 Potentiates cGAS Activation by Relieving SUMO-Mediated Inhibition of Cytosolic DNA Sensing
10.1371/journal.ppat.1006156 · 2017 · External reference
The role of protein SUMOylation in rheumatoid arthritis
10.1016/j.jaut.2019.05.006 · 2019 · External reference
The SUMO components in rheumatoid arthritis
10.1093/rheumatology/keac297 · 2022 · External reference
Role of small ubiquitin-like modifier proteins-1 (SUMO-1) in regulating migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis
10.1016/j.yexcr.2018.12.011 · 2019 · External reference
The Dynamic SUMOylation Changes and Their Potential Role in the Senescence of APOE4 Mice
10.3390/biomedicines12010016 · 2023 · External reference
Abeta-induced presynaptic release of UBC9 through extracellular vesicles involves SNAP23
10.1016/j.neulet.2022.136771 · 2022 · External reference
Degeneration of nigrostriatal dopaminergic neurons in the early to intermediate stage of dementia with Lewy bodies and Parkinson's disease
10.1016/j.jns.2023.120660 · 2023 · External reference
UBC9 mediates mitophagy to attenuate oxidative stress by regulating SUMOylation of PINK1 in the Parkinson’s disease progression
10.1007/s10565-025-10126-3 · 2025 · External reference
SUMOylation modulates mitochondrial dynamics in an in vitro rotenone model of Parkinson's disease
10.1016/j.mcn.2024.103969 · 2024 · External reference
Huntingtin and the Synapse
10.3389/fncel.2021.689332 · 2021 · External reference
Deletion of SUMO1 attenuates behavioral and anatomical deficits by regulating autophagic activities in Huntington disease
10.1073/pnas.2107187119 · 2022 · External reference
Dysregulation of protein SUMOylation networks in Huntington's disease R6/2 mouse striatum
10.1093/brain/awae319 · 2025 · External reference
Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma
10.1038/s41467-025-64665-8 · 2025 · External reference
10.1016/j.csbj.2015.03.001 · 2015 · Admitted local publication
Preliminary study on the synthesis and biological activity of small molecule #br# inhibitor JK043 of SUMO-specific protease 1
2016 · External reference
A Small-Molecule Microarray Approach for the Identification of E2 Enzyme Inhibitors in Ubiquitin-Like Conjugation Pathways
10.1177/2472555216683937 · 2017 · External reference
Targeting SUMOylation dependency in human cancer stem cells through a unique SAE2 motif revealed by chemical genomics
10.1016/j.chembiol.2021.04.014 · 2021 · External reference
1,10-phenanthroline inhibits sumoylation and reveals that yeast SUMO modifications are highly transient
10.1038/s44319-023-00010-8 · 2024 · External reference
Discovery of a Dual SENP1 and SENP2 Inhibitor
10.3390/ijms232012085 · 2022 · External reference
Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme
10.1038/s41467-018-07015-1 · 2018 · External reference
Unresolved reference
External reference
Unresolved reference
2015 · External reference
Identification of 1,2,5-Oxadiazoles as a New Class of SENP2 Inhibitors Using Structure Based Virtual Screening
10.1021/ci4007134 · 2014 · External reference
Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation
10.18632/oncotarget.10636 · 2016 · External reference
Streptooctatin A induces autophagy and promotes α-synuclein clearance by directly binding to SUMO2 and inhibiting SUMOylation
2025 · External reference
Ginkgolic Acid Inhibits Protein SUMOylation by Blocking Formation of the E1-SUMO Intermediate
10.1016/j.chembiol.2009.01.009 · 2009 · External reference
Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency
10.1371/journal.pone.0217578 · 2019 · External reference
Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
2019 · External reference
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma
10.1016/j.clml.2025.04.020 · 2025 · External reference
Unresolved reference
External reference
A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors
10.1200/jco.2022.40.16_suppl.2506 · 2022 · External reference
Ginkgoic acid impedes gastric cancer cell proliferation, migration and EMT through inhibiting the SUMOylation of IGF-1R
10.1016/j.cbi.2021.109394 · 2021 · External reference
Insights into SUMOylation in gastric cancer: molecular mechanisms and emerging therapeutic opportunities
10.1007/s00432-025-06382-9 · 2025 · External reference
Attenuation of arsenic trioxide-induced endothelial injury: unveiling the protective role of ginkgolic acid through inhibition of TRPM4 SUMOylation: Evidence from Raman cellular imaging
10.1002/viw.20250049 · 2026 · External reference
Hypoxia-mediated SUMOylation of FADD exacerbates endothelial cell injury via the RIPK1-RIPK3-MLKL signaling axis
10.1038/s41419-025-07441-2 · 2025 · External reference
An electrophoretic mobility shift assay identifies a mechanistically unique inhibitor of protein sumoylation
10.1016/j.chembiol.2013.04.001 · 2013 · External reference
2-D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2
10.1016/j.bbrc.2019.04.079 · 2019 · External reference
SUMOylation facilitates the stability of BCR-ABL to promote chronic myeloid leukemia progression
10.1038/s41388-025-03350-y · 2025 · External reference
Structural basis for a nucleoporin exportin complex between RanBP2, SUMO1-RanGAP1, the E2 Ubc9, Crm1 and the Ran GTPase
10.1038/s41467-025-61694-1 · 2025 · External reference
Streptooctatins A and B, fusicoccane-type diterpenoids with autophagic activity from Streptomyces sp. KCB17JA11
10.1016/j.bmcl.2021.128504 · 2022 · External reference
α-Synuclein pathology as a target in neurodegenerative diseases
10.1038/s41582-024-01043-w · 2025 · External reference
Discovery and radiosensitization research of ursolic acid derivatives as SENP1 inhibitors
10.1016/j.ejmech.2021.113918 · 2022 · External reference
Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme
10.1016/j.chembiol.2018.10.026 · 2019 · External reference
Discovery of 1-[4-(N-benzylamino)phenyl]-3-phenylurea derivatives as non-peptidic selective SUMO-sentrin specific protease (SENP)1 inhibitors
10.1016/j.bmcl.2012.06.084 · 2012 · External reference
Preliminary study on the synthesis and biological activity of small molecule inhibitor JK043 of SUMO-specific protease 1
2016 · External reference
Functional characterization of a SUMO deconjugating protease of Plasmodium falciparum using newly identified small molecule inhibitors
10.1016/j.chembiol.2011.04.010 · 2011 · External reference
Development of small molecule inhibitors and probes of human SUMO deconjugating proteases
10.1016/j.chembiol.2011.05.008 · 2011 · External reference
Therapeutic Potential of Targeting the SUMO Pathway in Cancer
10.3390/cancers13174402 · 2021 · External reference
Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy
10.3324/haematol.2022.280995 · 2023 · External reference
Targeting SUMO Signaling to Wrestle Cancer
10.1016/j.trecan.2020.11.009 · 2021 · External reference
Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC
10.1016/j.isci.2025.112555 · 2025 · External reference
Unraveling the critical role of SUMOylation in the governing of tumor immunity
2025 · External reference
Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer
10.7150/thno.79688 · 2023 · External reference
Mechanisms and functions of SUMOylation in health and disease: a review focusing on immune cells
10.1186/s12929-024-01003-y · 2024 · External reference
Limited SUMOylation inhibitor administration enhances eradication of Burkitt’s lymphoma with CD19 CAR-T therapy
10.1038/s41392-025-02422-5 · 2025 · External reference
Structural basis for the human SENP5's SUMO isoform discrimination
10.1038/s41467-025-60029-4 · 2025 · External reference
Cryo-EM structures reveal the molecular mechanism of SUMO E1–E2 thioester transfer
10.1038/s41594-025-01681-8 · 2025 · External reference
Prospective de novo drug design with deep interactome learning
10.1038/s41467-024-47613-w · 2024 · External reference
Optimizing drug design by merging generative AI with a physics-based active learning framework
10.1038/s42004-025-01635-7 · 2025 · External reference
Targeted protein degradation: from mechanisms to clinic
10.1038/s41580-024-00729-9 · 2024 · External reference
Identification of proximal SUMO-dependent interactors using SUMO-ID
10.1038/s41467-021-26807-6 · 2021 · External reference
The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation
10.1182/blood.2021014267 · 2022 · External reference
